Journal Logo

Articles by B. Falini

THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL: S104

Tiacci, E.; De Carolis, L.; Simonetti, E.; More

HemaSphere. 3:3, June 2019.

PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE: PF227

Caprioli, C.; Spinelli, O.; Salmoiraghi, S.; More

HemaSphere. 3:65-66, June 2019.